International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 113203 Total View: 1776985
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com
Article http://dx.doi.org/10.26855/ijcemr.2023.01.013

T-lymphocyte Subsets Assessment of the Efficacy of PD-L1 Inhibitors in Combination with Chemotherapy in the First-line Treatment of Elderly with Extensive-stage Small Cell Lung Cancer

Zhaoxue Lu1,3,*, Ying Li2,3, Xuguang Zhang2,3

1Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.

2Department of Radiation Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, China.

3First Clinical College, Xuzhou Medicine University, Xuzhou, Jiangsu, China.

*Corresponding author: Zhaoxue Lu

Published: February 6,2023

Abstract

Objective: To investigate the clinical efficacy of PD-L1 inhibitor combined with chemotherapy in the treatment of elderly extensive-stage small cell lung cancer and the changes of T lymphocyte subsets before and after treatment. Methods: Sixty-four elderly patients admitted to the Affiliated Hospital of Xuzhou Medical University from September 2020 to May 2022 who met the inclusion criteria for primary diagnosis of extensive-stage small cell lung cancer were selected, 34 patients in the control group and 30 patients in the observation group. All patients in the control group were given platinum-based etoposide regimen chemotherapy, while patients in the observation group were treated with dulvalizumab or atelelizumab combined with platinum-etoposide. The tumor markers, lymphocyte subsets, progression-free survival and depth of remission were compared between the two groups after 4 courses of treatment. Results: The CD3+, CD4+ and CD4+/CD8+ T lymphocyte ratios in the observation group were significantly higher than those in the control group, with statistically significant differences (P< 0.05) while there was no significant difference between the two CD8+ groups after treatment, (P> 0.05). Progression-free survival (7.5 months vs. 5.9 months, P = 0. 013), the depth of remission in the observation group was better than that in the control group. Conclusion: PD-L1 inhibitor combined with chemotherapy for distant metastatic small cell lung cancer effectively modulates T-lymphocyte subpopulation, improves the body's immune capacity, and achieves better survival benefit.

References

[1] Siegel, R.L., et al., Cancer statistics, 2022. CA Cancer J Clin, 2022. 72(1): p. 7-33.

[2] Govindan, R., et al., Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 2006. 24(28): p. 4539-44.

[3] Zelen, M., Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3, 1973. 4(2): p. 31-42.

[4] Kalemkerian, G.P., Small Cell Lung Cancer. Semin Respir Crit Care Med, 2016. 37(5): p. 783-796.

[5] Mansfield, A.S., et al., Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol, 2020. 31(2): p. 310-317.

[6] Paz-Ares, L., et al., Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, 2019. 394(10212): p. 1929-1939.

[7] Nishino, M., et al., Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol, 2017. 14(11): p. 655-668.

[8] Rathore, A.S., et al., CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res, 2014. 140(3): p. 361-9.

[9] Chen, Y., et al., Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer. Cancer Immunol Immunother, 2021. 70(10): p. 2867-2876.

[10] Sun, C., et al., Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer. Onco Targets Ther, 2020. 13: p. 6475-6483.

[11] Kamphorst, A.O., et al., Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A, 2017. 114(19): p. 4993-4998.

[12] Huang, A.C., et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017. 545(7652): p. 60-65.

[13] Miao, K., et al., Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Front Immunol, 2022. 13: p. 912180.

How to cite this paper

T-lymphocyte Subsets Assessment of the Efficacy of PD-L1 Inhibitors in Combination with Chemotherapy in the First-line Treatment of Elderly with Extensive-stage Small Cell Lung Cancer

How to cite this paper: Zhaoxue Lu, Ying Li, Xuguang Zhang. (2023) T-lymphocyte Subsets Assessment of the Efficacy of PD-L1 Inhibitors in Combination with Chemotherapy in the First-line Treatment of Elderly with Extensive-stage Small Cell Lung Cancer. International Journal of Clinical and Experimental Medicine Research7(1), 73-77.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.01.013